Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Depreciation & Amortization - Total (2016 - 2017)

Historic Depreciation & Amortization - Total for Altimmune (ALT) over the last 6 years, with Q1 2017 value amounting to $33007.0.

  • Altimmune's Depreciation & Amortization - Total fell 1245.06% to $33007.0 in Q1 2017 from the same period last year, while for Dec 2017 it was $33007.0, marking a year-over-year decrease of 7698.85%. This contributed to the annual value of $143437.0 for FY2016, which is 129.45% up from last year.
  • Per Altimmune's latest filing, its Depreciation & Amortization - Total stood at $33007.0 for Q1 2017, which was down 1245.06% from $33066.0 recorded in Q4 2016.
  • In the past 5 years, Altimmune's Depreciation & Amortization - Total registered a high of $52602.0 during Q1 2013, and its lowest value of $32235.0 during Q3 2016.
  • In the last 5 years, Altimmune's Depreciation & Amortization - Total had a median value of $37106.0 in 2015 and averaged $38264.3.
  • Its Depreciation & Amortization - Total has fluctuated over the past 5 years, first plummeted by 3845.25% in 2013, then surged by 1021.62% in 2016.
  • Over the past 5 years, Altimmune's Depreciation & Amortization - Total (Quarter) stood at $43438.0 in 2013, then fell by 15.54% to $36686.0 in 2014, then dropped by 10.58% to $32806.0 in 2015, then rose by 0.79% to $33066.0 in 2016, then fell by 0.18% to $33007.0 in 2017.
  • Its Depreciation & Amortization - Total stands at $33007.0 for Q1 2017, versus $33066.0 for Q4 2016 and $32235.0 for Q3 2016.